Loading...
Loading...
Browse all stories on DeepNewz
VisitFTC decision on Novo Holdings' acquisition of Catalent by end of 2024
Approval • 33%
Conditional Approval • 33%
Rejection • 34%
FTC announcements, major news outlets
FTC Extends Review of Novo Holdings' $16.5 Billion Catalent Acquisition
May 3, 2024, 03:05 PM
The U.S. Federal Trade Commission (FTC) has issued a second request for more information regarding the $16.5 billion acquisition of Catalent by Novo Nordisk's parent company, Novo Holdings. This move, part of an extended antitrust review, could delay the deal by an additional 30 days. The request reflects the FTC's ongoing scrutiny of the transaction amid concerns from other pharmaceutical groups and contract manufacturers.
View original story
Approval without conditions • 25%
Approval with conditions • 25%
Extended review • 25%
Rejection of the deal • 25%
No action • 33%
Settlement • 33%
Formal charges • 34%
No • 50%
Yes • 50%
Increase • 33%
Decrease • 33%
No significant change • 34%